Professor Claudia Nold, NHMRC Leadership Fellow

Bujotzek A, Tiefenthaler G, Lariviere L, D’Andrea L, Marquez EA, Rudloff I, Cho SX, Deen NS, Richter W, Regenass-Lechner F, Poehler A, Whisstock JC, Sydow-Andersen J, Reiser X, Schuster S, Neubauer J, Hoepfl S, Richter K, Nold MF, Nold-Petry CA, Schumacher F, Ellisdon AM (2022). Protein engineering of a stable and potent anti-inflammatory IL-37-Fc fusion with enhanced therapeutic potential. Cell Chem Biol. 2022 Apr 21;29(4):586-596.e4.

Christie MJ, Irving AT, Forster SC, Marsland BJ, Hansbro PM, Hertzog PJ, Nold-Petry CA, Nold MF (2022). Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci Immunol. 2021 Sep 17;6(63):eabd0205. doi: 10.1126/sciimmunol.abd0205. Epub 2021 Sep 17. PMID: 34533977.

Cho SX, Rudloff I, Lao JC, Pang MA, Goldberg R, Bui CB, McLean CA, Stock M, Klassert TE, Slevogt H, Mangan NE, Cheng W, Fischer D, Gfroerer S, Sandhu MK, Ngo D, Bujotzek A, Lariviere L, Schumacher F, Tiefenthaler G, Beker F, Collins C, Kamlin COF, König K, Malhotra A, Tan K, Theda C, Veldman A, Ellisdon AM, Whisstock JC, Berger PJ, Nold-Petry CA, Nold MF (2022). Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities. Nat Commun. 2020 Nov 13;11(1):5794.

Lao JC, Bui CB, Pang MA, Cho SX, Rudloff I, Elgass K, Schröder J, Maksimenko A, Mangan NE, Starkey MR, Skuza EM, Sun YBY, Beker F, Collins CL, Kamlin OF, König K, Malhotra A, Tan K, Theda C, Young MJ, McLean CA, Wilson NJ, Sehgal A, Hansbro PM, Pearson JT, Polo JM, Veldman A, Berger PJ, Nold-Petry CA, Nold MF (2022). Type 2 immune polarization is associated with cardiopulmonary disease in preterm infants. Sci Transl Med. 2022 Apr 6;14(639):eaaz8454.

Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, Ellisdon AM, Rotter B, Azam T, Mangan NE, Rossello FJ, Whisstock JC, Bufler P, Garlanda C, Mantovani A, Dinarello CA, Nold MF. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol, March 2015

Nold MF, Mangan NE, Rudloff I, Cho SX, Shariatian N, Samarasinghe TD, Skuza EM,Veldman A, Berger PJ, Nold-Petry, CA. Interleukin 1 receptor antagonist prevents murine BPD induced by perinatal inflammation and hyperoxia.PNAS 2013, 110(35):14384-89.

Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11(11):1014-22.

Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF. IL-32 promotes angiogenesis. J Immunol 2014, 192(2):589-602.

Zepp JA, Nold-Petry CA, Dinarello CA, Nold MF. Protection from RNA- and DNA-viruses by IL-32. J Immunol 2011, 186(7):4110-8. [featured among 10% best papers in the issue]

Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF, Dinarello CA. IL-32-dependent effects of IL-1beta on endothelial cells. Proc Natl Acad Sci USA 106(10):3883-8, March 2009

Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ, Kullberg BJ, Rubartelli A, van der Meer JW, Dinarello CA. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113(10):2324-35.